inHEART Secures $11 Million in Funding

by Kay Aloha Villamor in May 13th, 2024

inHEART, a France-based company that creates medical software utilizing AI, has secured $11 million in funding. 


Vesalius Biocapital IV and Elaia Partners led the investment, with participation from other investors such as NACO, Sagana, Sofia Angels Ventures, CWR Funds, and Webit Investment Network. Additionally, funds were obtained from a crowdfunding campaign on Tudigo and from the Astorg Foundation, managed by the King Baudouin Foundation. 

Vesalius Biocapital, founded in 2007, is a Luxembourg-based investment firm targeting early-stage investments in biotech and e-health-related companies primarily across Europe.

Elaia is a French venture capital firm focused on European digital and deep tech startups, from early stage to growth development. 

inHEART Use of Funds 

The company intends to use the funding to develop more advanced heart models capable of predicting heart failure, sudden heart attacks, and strokes caused by heart problems. 

About inHEART 

Founded in 2017, inHEART specializes in creating medical software that uses AI to generate digital versions of the heart, enabling doctors to perform cardiac ablation more effectively. Their current solution focuses on improving cardiac ablation, a procedure used to treat heart issues, by utilizing AI to create detailed 3D models of the heart from scans like CT or MRIs. inHEART's technology aims to improve the efficiency of care, quality of decision-making, and effectiveness and safety of medical interventions in addressing the needs of cardiac patients globally. 

Funding Details

Company: inHEART 

Raised: $11.0M 

Round: Unknown

Funding Month: May 2024 

Lead Investors: Vesalius Biocapital IV, Elaia Partners 

Additional Investors: NACO, Sagana, Sofia Angels Ventures, CWR Funds, Webit Investment Network 

Company Website: 

Software Category: Medical Software 


Your cart